IL37 and inflammatory bowel disease: Attention has been drawn recently by the IL-23/Th17 effector axis because of its potential as a therapeutic target and as a key passage to understanding the pathophysiology of psoriasis and IBD due to its synergy with intestinal mucosa cells and keratinocytes.